Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02742090 · ClinicalTrials.gov registry record · Phase 2
Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy
A Phase 2 study, sponsored by TG Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT02742090 is a Phase 2 study that was terminated before completion, run by TG Therapeutics. The registered enrollment target is 51 participants.
The verdict
NCT02742090, a Phase 2 study, was terminated before completion, sponsored by TG Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
The main objective of this study is to determine the progression free survival of umbralisib in participants who were intolerant to prior BTK (Bruton Tyrosine Kinase) inhibitors (ibrutinib, ACP-196, other) or prior PI3K-delta inhibitors (idelalisib, duvelisib, other).
Interventions
- DRUG Umbralisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2016-04-21 |
| Est. Completion | 2021-06-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02742090
The ClinicalTrials.gov registry entry for NCT02742090 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TG Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Umbralisib is the first listed.
NCT02742090 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02742090 about?
NCT02742090 is a clinical study titled "Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy". The main objective of this study is to determine the progression free survival of umbralisib in participants who were intolerant to prior BTK (Bruton Tyrosine Kinase) inhibitors (ibrutinib, ACP-196, other) or prior PI3K-delta inhibitors (idelalisib, duvelisib, other).
What is the current status of trial NCT02742090?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2016-04-21. Estimated completion is 2021-06-10.
What interventions are being tested in trial NCT02742090?
The interventions under investigation include: Umbralisib (DRUG).
Who is sponsoring clinical trial NCT02742090?
This trial is sponsored by TG Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.